Cabometyx

(Cabozantinib)

Phase 3Small molecule

Cabozantinib is used to treat certain types of cancer, including kidney cancer, liver cancer, and thyroid cancer. It works by blocking proteins that help cancer cells grow and spread.[1] Cabometyx is currently being investigated across 79 indications[3], with its most advanced program in Phase 3.[1]

Cabometyx is one of 1173 small molecule programs targeting Collecting Duct Carcinoma. It is currently in Phase 3.

Indications

245

Total Trials

Active Trials

1,172

Competitors

Pipeline

Status by Indication[3][1]

Indication

Collecting Duct CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

ParagangliomaActive, not recruiting

Salivary Gland CancerActive, not recruiting

Thyroid NeoplasmUnknown

Kidney CancerActive, not recruiting

Chromophobe Renal Cell CarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

Collecting Duct CarcinomaPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Thyroid NeoplasmPreclinical

Unknown

Kidney CancerPhase 2

Active, not recruiting

Chromophobe Renal Cell CarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Showing 10 of 79 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

2 2

Tecentriq

Roche

Preclinical

36 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Acupan

YYonsei University

Preclinical

1 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Endometrial Cancer

NCT03367741

Phase 3Active, not recruiting

Thyroid Cancer

NCT03690388

Phase 2Active, not recruiting

Neuroendocrine Tumors

NCT04079712

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT05092373

Phase 2Active, not recruiting

Soft Tissue Sarcoma

NCT04200443

Phase 1Active, not recruiting

Metastatic

NCT02496208

Clinical

Trials by Indication[1]

Renal Cell Carcinoma27 trials

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Recruiting·FFox Chase Cancer Center·Phase 2·NCT05263050·111 enrolled

Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed·CCentre Leon Berard·Phase 2·NCT03967522·26 enrolled

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Completed· Ipsen logo

Ipsen··NCT04353765·247 enrolled

Show 24 more trials

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed· Takeda logo

Takeda··NCT04804813·388 enrolled

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Completed·CCalithera Biosciences, Inc·Phase 2·NCT03428217·444 enrolled

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05048212·20 enrolled

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Terminated·GGenenta Science·Phase 1/2·NCT06716853·10 enrolled

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Unknown status·IIstituto Oncologico Veneto IRCCS··NCT04416646·100 enrolled

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 4·NCT06934057·50 enrolled

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05188118·20 enrolled

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07187869·16 enrolled

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03339219·35 enrolled

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Active, not recruiting·EExelixis·Phase 3·NCT03937219·855 enrolled

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03354884·23 enrolled

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03541902·32 enrolled

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Completed· Ipsen logo

Ipsen·Phase 2·NCT03945773·127 enrolled

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03634540·118 enrolled

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT02293980·110 enrolled

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05931393·18 enrolled

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Completed·EExelixis·Phase 3·NCT01865747·658 enrolled

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04300140·72 enrolled

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica··NCT06548867·80 enrolled

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03149822·45 enrolled

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed·UUniversity of Utah·Phase 1·NCT03200587·12 enrolled

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Terminated· Roche logo

Roche·Phase 3·NCT04338269·522 enrolled

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03141177·701 enrolled

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Terminated·NNektar Therapeutics·Phase 3·NCT03729245·623 enrolled

Hepatocellular Carcinoma14 trials

Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT04316182·24 enrolled

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Completed· Takeda logo

Takeda··NCT05100082·263 enrolled

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Withdrawn·OOHSU Knight Cancer Institute·Phase 2·NCT05327738

Show 11 more trials

Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)

Completed·HHospices Civils de Lyon·Phase 4·NCT03963206·110 enrolled

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Recruiting·IIterion Therapeutics·Phase 1/2·NCT05797805·178 enrolled

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03586973·34 enrolled

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Completed·EExelixis·Phase 3·NCT01908426·707 enrolled

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04511455·22 enrolled

A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function

Unknown status·JJohannes Gutenberg University Mainz·Phase 2·NCT04454762·20 enrolled

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

Not yet recruiting·—·Phase 2·NCT06535737·40 enrolled

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT04497038·3 enrolled

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03299946·15 enrolled

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Unknown status·IIstituto Clinico Humanitas·Phase 2·NCT04435977·46 enrolled

Cabozantinib in Hepatocellular Carcinoma

Active, not recruiting·SStephen Chan Lam·Phase 2·NCT04588051·20 enrolled

Prostate Cancer12 trials

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Recruiting·UUniversity of Utah·Phase 2·NCT05168618·33 enrolled

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01428219·25 enrolled

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Completed·EExelixis·Phase 3·NCT01605227·1,028 enrolled

Show 9 more trials

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Terminated·—·Phase 2·NCT03964337·3 enrolled

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Completed·WWashington University School of Medicine·Phase 1·NCT04477512·18 enrolled

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT01703065·9 enrolled

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Terminated·EExelixis·Phase 3·NCT01522443·119 enrolled

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01683994·49 enrolled

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Completed·—·Phase 2·NCT01834651·17 enrolled

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Completed·WWeill Medical College of Cornell University·Phase 2·NCT04631744·4 enrolled

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Completed·MMassachusetts General Hospital·Phase 1·NCT01347788·34 enrolled

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Completed·UUniversity of Chicago·Phase 2·NCT01599793·19 enrolled

Thyroid Cancer10 trials

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01811212·25 enrolled

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03914300·11 enrolled

Show 7 more trials

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Active, not recruiting·EExelixis·Phase 4·NCT01896479·247 enrolled

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03630120·6 enrolled

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruiting·FFujian Medical University·Phase 4·NCT07010393·335 enrolled

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT06475989·264 enrolled

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn· Roche logo

Roche·Phase 3·NCT04760288

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04211337·291 enrolled

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Active, not recruiting·EExelixis·Phase 3·NCT03690388·187 enrolled

Kidney Cancer9 trials

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02761057·152 enrolled

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835158·157 enrolled

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05411081·200 enrolled

Show 6 more trials

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Active, not recruiting·—·Phase 1·NCT05122546·31 enrolled

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Recruiting·MMark Stein·Phase 2·NCT04322955·48 enrolled

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04540705·30 enrolled

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07383441·718 enrolled

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Active, not recruiting·EEmory University·Phase 2·NCT04022343·22 enrolled

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 2·NCT05361720·54 enrolled

88 more indications

Non-Small Cell Lung Cancer8 trials

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Unknown status·FFondazione Ricerca Traslazionale·Phase 2·NCT03911193·25 enrolled

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05613413·36 enrolled

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01866410·37 enrolled

Show 5 more trials

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Terminated·LLiza Villaruz, MD·Phase 2·NCT02132598·5 enrolled

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Terminated·—·Phase 1·NCT04173338·9 enrolled

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04151563

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT04471428·366 enrolled

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01639508·86 enrolled

Soft Tissue Sarcoma5 trials

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04339738·89 enrolled

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting·—·Phase 2·NCT04200443·72 enrolled

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Active, not recruiting·NNational Cancer Institute LAO·Phase 2·NCT05836571·66 enrolled

Show 2 more trials

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04551430·105 enrolled

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01755195·55 enrolled

Liver Cancer4 trials

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT04442581·2 enrolled

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01658878·657 enrolled

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting·—·Phase 2·NCT05168163·122 enrolled

Show 1 more trial

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04204850·20 enrolled

Trial4 trials

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04427787·69 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Show 1 more trial

Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients

Not yet recruiting·—·Phase 2·NCT05241561·24 enrolled

Renal Carcinoma2 trials

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Recruiting·CCentre Francois Baclesse·Phase 4·NCT07028125·83 enrolled

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04134390·25 enrolled

Melanoma2 trials

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01835184·5 enrolled

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting·GGeorgetown University·Phase 2·NCT04091750·14 enrolled

Adrenocortical Carcinoma2 trials

Cabozantinib in Advanced Adrenocortical Carcinoma

Unknown status·WWuerzburg University Hospital·Phase 2·NCT03612232·37 enrolled

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03370718·18 enrolled

Endometrial Cancer2 trials

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01935934·102 enrolled

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03367741·82 enrolled

Advanced Cancer2 trials

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04514484·8 enrolled

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Completed·EExelixis·Phase 1·NCT01553656·85 enrolled

Pancreatic Cancer2 trials

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT01663272·12 enrolled

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT04820179·30 enrolled

Multiple Myeloma2 trials

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Completed·MMassachusetts General Hospital·Phase 1·NCT01582295·4 enrolled

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Terminated·UUniversity of Nebraska·Phase 1/2·NCT03201250·11 enrolled

Carcinoid Tumor2 trials

Cabozantinib and Nivolumab for Carcinoid Tumors

Completed·—·Phase 2·NCT04197310·19 enrolled

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Completed·—·Phase 2·NCT01466036·61 enrolled

Locally Advanced2 trials

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Recruiting·EEmory University·Phase 2·NCT06006013·21 enrolled

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Terminated·JJohannes Gutenberg University Mainz·Phase 2·NCT04066595·7 enrolled

Chemotherapy2 trials

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT06811116·92 enrolled

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Terminated·EExelixis·Phase 2·NCT01995058·54 enrolled

Neuroendocrine Tumors2 trials

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04079712·17 enrolled

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT05249114·6 enrolled

Metastatic Urothelial Cancer2 trials

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Recruiting·EEmory University·Phase 1·NCT04878029·32 enrolled

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05092958·654 enrolled

Metastatic Melanoma2 trials

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835145·47 enrolled

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Terminated·JJohn Rieth·Phase 1/2·NCT03957551·28 enrolled

Treatment2 trials

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05663710·100 enrolled

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Completed· Ipsen logo

Ipsen··NCT04637204·1,540 enrolled

Osteosarcoma2 trials

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Active, not recruiting· Ipsen logo

Ipsen·Phase 2·NCT06341712·10 enrolled

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05019703·40 enrolled

Plexiform Neurofibroma2 trials

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Not yet recruiting·GGirish Dhall, MD·Phase 1·NCT06502171·30 enrolled

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02101736·45 enrolled

Refractory Solid Tumors2 trials

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05038839·44 enrolled

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting·PPeter Zage·Phase 1·NCT03611595·18 enrolled

Head and Neck Squamous Cell Cancer2 trials

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Active, not recruiting·EEmory University·Phase 2·NCT03468218·36 enrolled

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03667482·20 enrolled

Advanced2 trials

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Active, not recruiting·—·Phase 2·NCT04413123·60 enrolled

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Active, not recruiting·KKarsten Gavenis·Phase 2·NCT04524208·45 enrolled

mCRPC2 trials

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Completed·AAlfredo Berruti·Phase 2·NCT05265988·32 enrolled

Metastatic1 trial

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02496208·152 enrolled

Temozolomide1 trial

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT04893785·35 enrolled

Nasopharyngeal Cancer1 trial

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05904080·50 enrolled

Relapsed/Refractory1 trial

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Recruiting·—·Phase 1·NCT06156410·30 enrolled

Esophageal Adenocarcinoma1 trial

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Active, not recruiting·UUniversity of California, Irvine·Phase 2·NCT04164979·34 enrolled

Pediatric Solid Tumors1 trial

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05135975·86 enrolled

mCRC1 trial

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled

Primary Peritoneal Cavity Cancer1 trial

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01716715·111 enrolled

Radiation Therapy1 trial

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Terminated·UUniversity of Washington·Phase 1/2·NCT04220229·6 enrolled

Recurrent or Refractory Solid Tumors1 trial

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01709435·41 enrolled

Metastatic Prostate Cancer1 trial

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT01812668·20 enrolled

Primary Peritoneal Cancer1 trial

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02315430·13 enrolled

Immunodeficiency1 trial

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01822522·36 enrolled

Cervical Cancer1 trial

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Terminated·UUniversity of South Alabama·Phase 2·NCT04230954·5 enrolled

Paraganglioma1 trial

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02302833·21 enrolled

Ewing sarcoma1 trial

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02243605·90 enrolled

Patients With Advanced Solid Tumors1 trial

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05092373·43 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Wilms tumor1 trial

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02867592·109 enrolled

Neuroendocrine Neoplasm1 trial

Cabozantinib in High Grade Neuroendocrine Neoplasms

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04412629·35 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Completed·—·Phase 2·NCT03316586·18 enrolled

Carcinosarcoma1 trial

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT04149275

Refractory1 trial

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Active, not recruiting·JJennifer King·Phase 2·NCT04876456·50 enrolled

Triple Negative1 trial

Cabozantinib for Metastatic Triple Negative BrCa

Completed·—·Phase 2·NCT01738438·35 enrolled

Differentiated Thyroid Carcinoma1 trial

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Unknown status·TThomas Jefferson University·Phase 2·NCT02041260·43 enrolled

Advanced Solid Malignancies1 trial

Cabozantinib in Advanced Solid Malignancies

Completed·MMassachusetts General Hospital·Phase 2·NCT01588821·37 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting·EExelixis·Phase 1·NCT03170960·914 enrolled

Pembrolizumab1 trial

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Completed·JJoseph Kim·Phase 2·NCT05052723·21 enrolled

Neoplasms1 trial

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT04400474·93 enrolled

Terminated·—·Phase 2·NCT02036476·8 enrolled

Acute Myeloid Leukemia1 trial

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT01961765·18 enrolled

Advanced Urothelial Cancer1 trial

Cabozantinib for Advanced Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688999·69 enrolled

Uterine Sarcoma1 trial

IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01979393·58 enrolled

GIST1 trial

Ph II CABOGIST in GIST

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02216578·51 enrolled

Advanced Malignancies1 trial

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Completed·EExelixis·Phase 2·NCT00940225·730 enrolled

Cutaneous Melanoma1 trial

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Terminated·PProvidence Health & Services·Phase 2·NCT05200143·4 enrolled

Adult Subject1 trial

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Completed·EExelixis·Phase 1·NCT01493869·26 enrolled

Central Nervous System Tumor1 trial

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Terminated·IIndiana University·Phase 2·NCT02885324·4 enrolled

Clinical Trial1 trial

CARE1 Pragmatic Clinical Trial

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06364631·1,250 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Precision Therapy in Refractory Tumor

Unknown status·BBaodong Qin·Phase 2·NCT03239015·300 enrolled

Endocrine Cancer1 trial

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Completed·MM.D. Anderson Cancer Center·N/A·NCT02592356·23 enrolled

Tyrosine Kinase Inhibitor1 trial

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05039736

Meningioma1 trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Recruiting·BBaptist Health South Florida·Phase 2·NCT05425004·24 enrolled

Colorectal Cancer1 trial

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04963283·48 enrolled

Impaired Renal Function1 trial

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Completed·EExelixis·Phase 1·NCT01761773·32 enrolled

Metastatic Renal Cell Cancer1 trial

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05012371·90 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·NNational Taiwan University Hospital·Phase 2·NCT05007613·24 enrolled

Relapsed or Refractory1 trial

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01866293·11 enrolled

Pancreatic Adenocarcinoma1 trial

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Terminated·PPatrick Joseph Loehrer Sr.·Phase 2·NCT03213626·7 enrolled

Phase II1 trial

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

Unknown status·UUniversity of Bologna·Phase 2·NCT04131543·25 enrolled

Cholangiocarcinoma1 trial

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01954745·19 enrolled

Breast Cancer1 trial

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Completed·—·Phase 2·NCT02260531·36 enrolled

Cytoreductive Nephrectomy1 trial

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Terminated·FFundacion Oncosur·Phase 2·NCT06377722·18 enrolled

Relapse1 trial

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Terminated·EExelixis·Phase 2·NCT01068782·19 enrolled

Genomic Alterations1 trial

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02795156·100 enrolled

Metastatic NSCLC1 trial

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Not yet recruiting·JJun Zhang, MD, PhD·Phase 2·NCT05859217·40 enrolled

Metastatic Colorectal Cancer1 trial

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Completed·JJohn Strickler, M.D.·Phase 1·NCT02008383·29 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT05048901·49 enrolled

Squamous Cell Carcinoma1 trial

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03943602·37 enrolled

Advanced Stage1 trial

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting·HHumanity & Health Medical Group Limited·Phase 2·NCT03899428·30 enrolled

Durvalumab1 trial

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03824691·122 enrolled

Unspecified4 trials

XL-184+Abiraterone in Post-Chemo CRPC

Completed·—·Phase 1·NCT01574937·27 enrolled

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

Recruiting·Ddr. Tom van der Hulle·Phase 2·NCT07077161·34 enrolled

Show 1 more trial

Spanish Real-World Evidence Cabozantinib

Completed·SSpanish Oncology Genito-Urinary Group··NCT04510688·275 enrolled

Sources

References

[1]
ClinicalTrials.gov — 245 trial records for Cabozantinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cabozantinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cabozantinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 1 publication indexed for Cabozantinib. U.S. National Library of Medicine.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Multi-Kinase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Key Publications[4]

Cabozantinib Plus Nivolumab in Advanced Renal Cell Carcinoma: CheckMate 9ER

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2205821

Cabometyx

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Renal Cell Carcinoma27 trials

Hepatocellular Carcinoma14 trials

Prostate Cancer12 trials

Thyroid Cancer10 trials

Kidney Cancer9 trials

Non-Small Cell Lung Cancer8 trials

Soft Tissue Sarcoma5 trials

Liver Cancer4 trials

Trial4 trials

Renal Carcinoma2 trials

Melanoma2 trials

Adrenocortical Carcinoma2 trials

Endometrial Cancer2 trials

Advanced Cancer2 trials

Pancreatic Cancer2 trials

Multiple Myeloma2 trials

Carcinoid Tumor2 trials

Locally Advanced2 trials

Chemotherapy2 trials

Neuroendocrine Tumors2 trials

Metastatic Urothelial Cancer2 trials

Metastatic Melanoma2 trials

Treatment2 trials

Osteosarcoma2 trials

Plexiform Neurofibroma2 trials

Refractory Solid Tumors2 trials

Head and Neck Squamous Cell Cancer2 trials

Advanced2 trials

mCRPC2 trials

Metastatic1 trial

Temozolomide1 trial

Nasopharyngeal Cancer1 trial

Relapsed/Refractory1 trial

Esophageal Adenocarcinoma1 trial

Pediatric Solid Tumors1 trial

mCRC1 trial

Primary Peritoneal Cavity Cancer1 trial

Radiation Therapy1 trial

Recurrent or Refractory Solid Tumors1 trial

Metastatic Prostate Cancer1 trial

Primary Peritoneal Cancer1 trial

Immunodeficiency1 trial

Cervical Cancer1 trial

Paraganglioma1 trial

Ewing sarcoma1 trial

Patients With Advanced Solid Tumors1 trial

Renal Cancer1 trial

Wilms tumor1 trial

Neuroendocrine Neoplasm1 trial

Triple-Negative Breast Cancer1 trial

Carcinosarcoma1 trial

Refractory1 trial

Triple Negative1 trial

Differentiated Thyroid Carcinoma1 trial

Advanced Solid Malignancies1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Pembrolizumab1 trial

Neoplasms1 trial

Function1 trial

Immunotherapy1 trial

Merkel Cell Carcinoma1 trial

Acute Myeloid Leukemia1 trial

Advanced Urothelial Cancer1 trial

Uterine Sarcoma1 trial

GIST1 trial

Advanced Malignancies1 trial

Cutaneous Melanoma1 trial

Adult Subject1 trial

Central Nervous System Tumor1 trial

Clinical Trial1 trial

Efficacy and Safety1 trial

Endocrine Cancer1 trial

Tyrosine Kinase Inhibitor1 trial

Meningioma1 trial